Our mission is to treat osteoarthritis and get people moving without pain.

about

Sparta is creating the first-of-its-kind chemically engineered cartilage platform, Galene.

The degeneration of cartilage between the joints can cause significant personal, economic, societal burden for individuals, families, and communities. In addition, acute injuries to joint cartilage can exacerbate and become debilitating over time.

We are developing cartilage-like implants for the knee and all of the important joints in the body.

solving a massive problem that affects the world’s population
address cartilage degeneration
intersection of chemistry, mechanical engineering, biology

Galene is a Multi-Indication Platform

Shoulder
Thumb
Partial knee
Ormi™
Patella
Elbow
Hip
Trochlea
Ankle
Toe

Leadership team

We are a team of operators, technologists, scientists, and engineers with long histories in the pharma, medtech, and nuclear arenas, and are driven by a common purpose; we seek to advance the standard of care for osteoarthritis and get people moving again without pain.

Dushyanth Surakanti
Dushyanth Surakanti
CEO & Co-Founder
Dimitrios Angelis
Dimitrios Angelis
President & Co-Founder
Benjamin Wiley, PhD
Benjamin Wiley, PhD
CTO & Lead Inventor
Demetrius Siachames, PE
Demetrius Siachames, PE
VP & Head of Engineering
Travis Entrop
Travis Entrop
Senior R&D Engineer
Board of directors
Ken Gall, PhD
Independent Director
Independent Director
Neil S. Roth, MD
Independent Director
Independent Director
Sean Fontenot
Independent Director
Independent Director
Dimitrios Angelis
President & Co-Founder
Executive Director
Executive Director
Dushyanth Surakanti
CEO & Co-Founder
Executive Director
Executive Director
Scientific Advisory Board
Adam Yanke, MD, PhD
Kristofer J. Jones, MD
Jon Dickens, MD, LTC
Brian Waterman, MD
Seth Sherman, MD
Strategic Advisory Board
Artem Iaryguine
Artem Iaryguine
Strategic Advisor
Nick Pachuda, DPM
Nick Pachuda, DPM
Strategic Advisor
Kristen Moffat, PhD
Kristen Moffat, PhD
Strategic Advisor

Are you experiencing knee problems?

Please sign up to be notified of our development progress and the initiation of our clinical study.

Click here to Continue

Clinical need

651M
People with knee osteoarthritis worldwide
16M
Annual visits as a result of knee pain
1.2M
Knee Cartilage repair procedures by 2030

We all have friends and family who are suffering from knee pain and limited range of motion. This is not only a problem locally, but globally. Over 500M suffer from osteoarthritis (OA). There are 16M visits in the US specifically for knee symptoms. In addition, there are hundreds of thousands osteochondral repairs per year. Unfortunately, there is a high percentage of patients who have a revision within two years. In addition, there are several million people getting a total knee replacement each year. A third of them were considered inappropriate candidates for this intervention. This issue also afflicts active military. Limited duty days exceed 1M after chondral procedures. One in three veterans have OA. The overall prevalence of knee cartilage lesions in high performance athletes is almost 40%.

our approach

The condition of any given joint is not just a result of chronological age, but also biological age - prior injury, daily routine, profession, and diet.

Galene, our proprietary bionic cartilage, renders biological age irrelevant.

Unlike cartilage regeneration technologies which take months, if not years, to fully regenerate cartilage, Galene replicates the physical properties of native human hyaline cartilage immediately. With optimized geometry based on anatomical locations, our technology has the potential to allow us to precisely and effectively address the needs of patients afflicted with osteoarthritis and cartilage defects, providing patients with immediate pain reduction and full range of motion, resulting in a quality of life they deserve.

The OrmiTM implant, a Breakthrough Device, was created by combining Galene with an osseointegrative titanium base. OrmiTM is intended to treat chondral and osteochondral lesions of the femoral condyle.

immediate pain reduction
+
full range of motion
=
enhanced quality of life

The Treatment Gap

Current technologies and treatments for cartilage defects have severe limitations. Click here to learn about the different surgical treatments available, and how they fall short next to Ormi™.

Read more

Clinical Benefit

A Target Product Profile (TPP) is a set of outcomes that focuses our efforts on building a solution that meaningfully improves that standard of care. Along with satisfying many safety requirements, we set a high bar on those outcomes that matter most for patients. Our TPP is unmatched by existing treatments and technologies in development. We believe this will instill confidence in surgeons as they help their patients quickly resume their daily routines and while knowing many productive years lay ahead.

Surgeons can take comfort in knowing their patients will quickly resume their routines and have highly productive lives many years to come.

Biologic / Cartilage Regeneration*
OrmiTM
Dependent on patient’s biology
Yes
No
Full weight bearing
Pain reduction
Several weeks
1-2 days
Achieve full range of motion
Several days/weeks
Few days
Return to biking, jogging, sports
in 6-24 months
Within few weeks
Durability
5 years
At least 10yrs

Pipeline

We are building a substantial pipeline of OrmiTM solutions. We will leverage all the know-how and preclinical testing from our knee indication and create efficient and cost effective development paths for these additional indications.

Indication
Prototype
Pre-Clinical
Clinical
Femoral condyle
Unicondylar
Patella
Trochlea
CMC
MTP
Shoulder
Hip
Elbow
Talus

IN the news

Oct 10, 2022
Sep 27, 2022
Sep 13, 2022
Aug 18, 2022

PRESS RELEASES

MedTech Innovator Announces 2023 Grand Prize Finalists
MedTech Innovator Announces 2023 Grand Prize Finalists
09/28/2023
Sparta Biomedical Closes an Oversubscribed Convertible Round to Advance its Breakthrough Device
Sparta Biomedical Closes an Oversubscribed Convertible Round to Advance its Breakthrough Device
09/12/2023
Sparta Biomedical's Breakthrough Device, Ormi, to be Featured at the 17th ICRS World Congress on September 10, 2023
Sparta Biomedical's Breakthrough Device, Ormi, to be Featured at the 17th ICRS World Congress on September 10, 2023
09/08/2023
Sparta Biomedical Celebrates Prestigious Recognition in MedTech and Significant Milestone
Sparta Biomedical Celebrates Prestigious Recognition in MedTech and Significant Milestone
08/24/2023
Sparta Biomedical to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
Sparta Biomedical to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
02/28/2023
Sparta Biomedical Raises $5M in Series Seed Financing to Advance its Breakthrough Device for Partial Knee Resurfacing
Sparta Biomedical Raises $5M in Series Seed Financing to Advance its Breakthrough Device for Partial Knee Resurfacing
12/14/2021
Sparta Biomedical Receives FDA Breakthrough Device Designation for SBM-01 Biomimetic Implant
Sparta Biomedical Receives FDA Breakthrough Device Designation for SBM-01 Biomimetic Implant
03/17/2021

RESOURCES

Sparta Biomedical Investor Deck (password protected)
Sparta Biomedical Investor Deck (password protected)
March 2023
Kyle Rose | Innovation remains intact: updates on 31 noteworthy private MedTech players
Kyle Rose | Innovation remains intact: updates on 31 noteworthy private MedTech players
March 2023
Hear the Last 10 Start-ups Standing in MedTech Innovator’s Pitch Competitions
Hear the Last 10 Start-ups Standing in MedTech Innovator’s Pitch Competitions
9/30/2023
The Edge of Knowledge
The Edge of Knowledge
08/28/2023, WABASH Magazine
Dimitrios Angelis Presents Sparta Biomedical at LSI USA '23 Emerging MedTech Summit
Dimitrios Angelis Presents Sparta Biomedical at LSI USA '23 Emerging MedTech Summit
Ben Wiley discusses Innovation in Bionic Cartilage on Angry@Arthritis Podcast
Ben Wiley discusses Innovation in Bionic Cartilage on Angry@Arthritis Podcast
06/19/2023
Ben Wiley and Sparta Biomedical Impacting Cartilage
Ben Wiley and Sparta Biomedical Impacting Cartilage
12/15/2022

Contact us

Thank you! Your submission has been received.
We will send you an email when we have updates to share.
Oops! Something went wrong while submitting the form.